Literature DB >> 11084189

Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997.

J F Egan1, P Benn, A F Borgida, J F Rodis, W A Campbell, A M Vintzileos.   

Abstract

OBJECTIVE: To estimate the 16-week prevalence of Down syndrome in the United States from 1974 to 1997 and to determine the efficacy of maternal age cutoffs and triple screens for detecting it antenatally.
METHODS: Using natality statistics for the United States from 1974 to 1997 of maternal-age-specific live births to women 13-49 years old, we evaluated advanced maternal age (35-49 years at delivery) and the triple serum test (maternal serum alpha-fetoprotein, hCG, and unconjugated estriol) as screening tests for Down syndrome. Efficacy was evaluated using sensitivity, false-positive rate, positive predictive value, and likelihood ratio (likelihood ratio = sensitivity/false-positive rate).
RESULTS: In 1974, the estimated second-trimester prevalence of Down syndrome was one in 740, but by 1997 that had increased to one in 504. The proportion of Down syndrome fetuses at 16 weeks' gestation in women 35-49 years old increased from 28.5% in 1974 to 47.3% in 1997. However, live births to women 35-49 years old increased more rapidly from 4.7% in 1974 to 12.6% in 1997. The likelihood ratio for maternal age to identify an affected pregnancy decreased during the study period and was substantially lower than that using the serum test.
CONCLUSION: A maternal age cutoff of 35 years in the 1990s resulted in high false-positive rates and was less efficacious based on likelihood ratio and positive predictive value. Serum testing of all pregnant women would reduce the number of amniocenteses and decrease procedure-related losses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084189     DOI: 10.1016/s0029-7844(00)01044-9

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

Review 1.  Recent developments in fetal medicine.

Authors:  Sailesh Kumar; Anna O'Brien
Journal:  BMJ       Date:  2004-04-24

2.  A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000.

Authors:  Babak Khoshnood; Catherine De Vigan; Véronique Vodovar; Janine Goujard; François Goffinet
Journal:  BJOG       Date:  2004-05       Impact factor: 6.531

Review 3.  Transcervical retrieval of fetal cells in the practice of modern medicine: a review of the current literature and future direction.

Authors:  Anthony N Imudia; Sanjeev Kumar; Michael P Diamond; Alan H DeCherney; D Randall Armant
Journal:  Fertil Steril       Date:  2010-01-13       Impact factor: 7.329

4.  Influence of second-trimester ultrasound markers for Down syndrome in pregnant women of advanced maternal age.

Authors:  Mariza Rumi Kataguiri; Edward Araujo Júnior; Luiz Claudio Silva Bussamra; Luciano Marcondes Machado Nardozza; Antonio Fernandes Moron
Journal:  J Pregnancy       Date:  2014-03-25

Review 5.  Non-invasive prenatal screening: A 20-year experience in Italy.

Authors:  Chiara Palka; Paolo Guanciali-Franchi; Elisena Morizio; Melissa Alfonsi; Marco Papponetti; Giulia Sabbatinelli; Giandomenico Palka; Giuseppe Calabrese; Peter Benn
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-18

Review 6.  Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome.

Authors:  Panagiotis Antsaklis; Zacharias Fasoulakis; Marianna Theodora; Michail Diakosavvas; Emmanuel N Kontomanolis
Journal:  Cureus       Date:  2019-06-17

7.  The impact of prenatal screening tests on prenatal diagnosis in Taiwan from 2006 to 2019: a regional cohort study.

Authors:  Ching Hua Hsiao; Ching Hsuan Chen; Po Jen Cheng; Steven W Shaw; Woei Chyn Chu; Ran Chou Chen
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-09       Impact factor: 3.007

8.  Non-invasive prenatal detection of trisomy 13 using a single nucleotide polymorphism- and informatics-based approach.

Authors:  Megan P Hall; Matthew Hill; Bernhard Zimmermann; Styrmir Sigurjonsson; Margaret Westemeyer; Jennifer Saucier; Zachary Demko; Matthew Rabinowitz
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.